Interpace Biosciences Posts Q3 Revenue of $10.4 Million, Adjusted EBITDA of $2.1 Million
Interpace Biosciences reported third-quarter 2026 revenue of $10.4 million, up 18% year over year, and an operating loss of $2.4 million. Net loss was $1.6 million, including approximately $4.1 million in non-recurring stock compensation and legal expenses, while Adjusted EBITDA was $2.1 million.Fi…